[go: up one dir, main page]

WO2012047893A3 - Use of rifazil and analogues thereof to treat ocular disorders - Google Patents

Use of rifazil and analogues thereof to treat ocular disorders Download PDF

Info

Publication number
WO2012047893A3
WO2012047893A3 PCT/US2011/054775 US2011054775W WO2012047893A3 WO 2012047893 A3 WO2012047893 A3 WO 2012047893A3 US 2011054775 W US2011054775 W US 2011054775W WO 2012047893 A3 WO2012047893 A3 WO 2012047893A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
rifazil
analogues
compositions
ocular disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/054775
Other languages
French (fr)
Other versions
WO2012047893A2 (en
Inventor
Chalom Sayada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Activbiotics Pharma LLC
Original Assignee
Activbiotics Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activbiotics Pharma LLC filed Critical Activbiotics Pharma LLC
Priority to CA2813734A priority Critical patent/CA2813734A1/en
Priority to BR112013008186A priority patent/BR112013008186A2/en
Publication of WO2012047893A2 publication Critical patent/WO2012047893A2/en
Publication of WO2012047893A3 publication Critical patent/WO2012047893A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions and methods for treating or preventing ocular bacterial infections, or disorders associated with such infections, are disclosed. The compositions include rifalazil or rifalazil derivatives, and optionally include other antimicrobial agents and/or anti-inflammatory agents. The compositions can be used to treat bacterial infections and associated ocular disorders. Trachoma and bacterial conjunctivitis are representative bacterial disorders that can be treated.
PCT/US2011/054775 2010-10-04 2011-10-04 Use of rifazil and analogues thereof to treat ocular disorders Ceased WO2012047893A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2813734A CA2813734A1 (en) 2010-10-04 2011-10-04 Use of rifalazil and analogues thereof to treat ocular disorders
BR112013008186A BR112013008186A2 (en) 2010-10-04 2011-10-04 use of ripazil and analogues to treat eye problems

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38942910P 2010-10-04 2010-10-04
US61/389,429 2010-10-04

Publications (2)

Publication Number Publication Date
WO2012047893A2 WO2012047893A2 (en) 2012-04-12
WO2012047893A3 true WO2012047893A3 (en) 2012-08-02

Family

ID=45928380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/054775 Ceased WO2012047893A2 (en) 2010-10-04 2011-10-04 Use of rifazil and analogues thereof to treat ocular disorders

Country Status (3)

Country Link
BR (1) BR112013008186A2 (en)
CA (1) CA2813734A1 (en)
WO (1) WO2012047893A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
WO2002100437A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic compositions comprising hyaluronic acid
US20050143374A1 (en) * 2001-09-06 2005-06-30 Activbiotics, Inc. Antimicrobial agents and uses thereof
JP2009120572A (en) * 2007-11-16 2009-06-04 Kaneka Corp Anti-inflammatory agent or immunomodulator having rifamycin derivative as active ingredient

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
WO2002100437A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic compositions comprising hyaluronic acid
US20050143374A1 (en) * 2001-09-06 2005-06-30 Activbiotics, Inc. Antimicrobial agents and uses thereof
JP2009120572A (en) * 2007-11-16 2009-06-04 Kaneka Corp Anti-inflammatory agent or immunomodulator having rifamycin derivative as active ingredient

Also Published As

Publication number Publication date
CA2813734A1 (en) 2012-04-12
WO2012047893A2 (en) 2012-04-12
BR112013008186A2 (en) 2016-06-21

Similar Documents

Publication Publication Date Title
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
IL213489A0 (en) Compositions and methods for the treatment of the prevention of e. coli infections and for the eradication or reduction of e. coli surfaces
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
GB2480772B (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
MX2015011898A (en) Pyrazolo compounds and uses thereof.
MX340533B (en) 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections.
WO2015003816A3 (en) Cystobactamides
WO2013163190A8 (en) Dna-pk inhibitors
EA033311B1 (en) Benzoxaborole derivatives as antibacterial agents
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
MX2015007556A (en) Mannose derivatives for treating bacterial infections.
WO2013078259A3 (en) Oil compositions and methods for increasing hair growth and/or preventing hair loss
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
MX372858B (en) WATER TREATMENT SYSTEMS AND METHODS.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
AU2010306647A8 (en) Antimicrobial compounds and methods of making and using the same
WO2013123249A3 (en) Formulations and methods for treating ear conditions
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
WO2009126695A3 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
MX2017012539A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11831455

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2813734

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11831455

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013008186

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013008186

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130404